Skip to main content

PerkinElmer Value Stock - Dividend - Research Selection

Perkinelmer

ISIN: US7140461093 , WKN: 850943

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, research, environmental, industrial, food, and laboratory services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment develops and offers analytical technologies, solutions, and services for the environmental market that enable its customers to understand the characterization and health of various aspects, including air, water, and soil. It also provides solutions to farmers and food producers; an analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries; and laboratory services. In addition, this segment offers a suite of solutions comprising reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market. The Diagnostics segment provides instruments, reagents, and software test and screen products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used in diagnosing genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for use in applications covering oncology, genetic testing, and drug discovery. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. has a collaboration agreement with Helix. The company was founded in 1931 and is headquartered in Waltham, Massachusetts.
The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


PerkinElmer Inc. stock outperforms market on strong trading day

2023-03-20
Shares of PerkinElmer Inc. inched 0.99% higher to $123.77 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P...

PerkinElmer Inc. stock falls Friday, underperforms market

2023-03-17
Shares of PerkinElmer Inc. slipped 2.79% to $122.56 Friday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500...

PerkinElmer Inc. stock underperforms Thursday when compared to competitors despite daily gains

2023-03-16
Shares of PerkinElmer Inc. rose 2.89% to $126.08 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...

May 19th Options Now Available For PerkinElmer (PKI)

2023-03-16
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

PerkinElmer Inc. stock outperforms market despite losses on the day

2023-03-15
Shares of PerkinElmer Inc. slipped 0.63% to $122.54 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P...

PerkinElmer Inc. stock outperforms competitors on strong trading day

2023-03-14
Shares of PerkinElmer Inc. advanced 2.63% to $123.32 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...

Parkland Corporation Announces First Quarter 2023 Dividend

2023-03-13
Parkland Corporation ("Parkland") (TSX: PKI) announces that a dividend of $0.34 per share will be paid on April 14, 2023 to shareholders of record on March 22, 2023. The dividend will be an 'eligible dividend' for Canadian income tax purposes. The ex-dividend date is March 21, 2023.

PerkinElmer Completes Divestiture of its Applied, Food and Enterprise Services Businesses

2023-03-13
WALTHAM, Mass., March 13, 2023--PerkinElmer Inc. (NYSE: PKI), today announced that it has successfully completed the previously announced divestiture of its Applied, Food and Enterprise Services businesses to New Mountain Capital, a growth-oriented investment firm.

PerkinElmer Inc. stock underperforms Monday when compared to competitors

2023-03-13
Shares of PerkinElmer Inc. slumped 0.06% to $120.16 Monday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500...

Video: S&P 500 Analyst Moves: PKI

2023-03-13
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.